Integrated Biosciences

Executive Summary

Integrated Biosciences is a private biotechnology company founded in 2021 that combines optogenetics, synthetic biology, chemistry, and artificial intelligence to discover novel small molecule therapeutics targeting age-related diseases. The company's proprietary platform leverages pioneering research from MIT, validated by high-impact publications in journals such as Nature and Cell. By integrating these diverse disciplines, Integrated Biosciences aims to systematically identify compounds that can modulate biological pathways associated with aging, with the ultimate goal of rewriting the biology of aging itself. The company's approach offers a unique, multi-dimensional strategy for drug discovery, potentially addressing a broad range of indications beyond traditional small molecule targets. Despite being in its early stages, the company has established a strong scientific foundation and is positioned to advance its pipeline toward preclinical and clinical development.

Upcoming Catalysts (preview)

• Q3 2026Publication of Preclinical Data in Peer-Reviewed Journal80% success
• Q4 2026Series A Financing Round70% success
• Q2 2027Initiation of IND-Enabling Studies for Lead Candidate60% success